BridGene Biosciences

BridGene Biosciences

  • Founded: 2018
  • Location: San Jose, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: Undisclosed
  • Product link:
  • Funding: $38.5M B Jul 2022; $12M A May 2021
  • Investors:  Lapam Capital, Junson Capital, Dyee Capital

job board

Short description:

Small molecules that drug traditionally undruggable targets

Drug notes:

3 additional undisclosed programs RD oncology

Long description:

BridGene Biosciences is developing small molecules intended to target previously undruggable targets. Currently, about 90% of disease-associated diseases cannot be targeted by traditional therapies as addressable binding sites are unknown. BridGene is using their chemoproteomics platform, IMTACTM, to screen small molecules against all proteins in live cells to discover drug candidates for high value and hard-to-drug targets. The IMTACTM platform uses covalent chemistry, chemical proteomics and quantitative mass spectrometry to screen cells in different cellular states and different cell compartments to greatly increase the application scope of BridGene’s chemoproteomic technology. Using their platform, BridGene is advancing a deep and diversified pipeline focusing on new oncology drugs.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy